Although clinically significant liver injury is extremely rare from statins, mild increases in liver enzymes can occur in 1%–3% of patients. Because of the concern of possible
hepatotoxicity, statins are labeled as contraindicated in patients with liver disease. Given the prevalence of liver diseases in the population, such as nonalcoholic fatty liver disease (NAFLD), hepatitis C (HCV), and others, many patients have not benefitted from the cardiovascular protective effects of statins.